ME02047B - Nova jedinjenja koja se vezuju za fxr (nr1 h4) i moduliraju njegovu aktivnost - Google Patents

Nova jedinjenja koja se vezuju za fxr (nr1 h4) i moduliraju njegovu aktivnost

Info

Publication number
ME02047B
ME02047B MEP-2015-18A MEP1815A ME02047B ME 02047 B ME02047 B ME 02047B ME P1815 A MEP1815 A ME P1815A ME 02047 B ME02047 B ME 02047B
Authority
ME
Montenegro
Prior art keywords
cyclopropyl
phenyl
prophylaxis
treatment
methoxy
Prior art date
Application number
MEP-2015-18A
Other languages
English (en)
Inventor
Claus Kremoser
Ulrich Abel
Christoph Steeneck
Olaf Kinzel
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of ME02047B publication Critical patent/ME02047B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (15)

1. Jedinjenje prema sledećoj formuli (1), njegov enantiomer, diastereomer, tautomer ili farmaceutski prihvatljiva sogdeR je izabran iz grupe koju čini COOR6, CONR7R8, tetrazolil ili H, gde je R6 nezavisno izabran iz grupe koju čini H, ili C1-6 alkil, i R7 i R8 međusobno nezavisno izabrani iz grupe koju čine H, C1-6 alkil, C1-6 haloalkil, C1-6 alkilen-R9, SO2-C1-6 alkil gde je R9 izabran iz grupe koju čine COOH, OH, ili SO3H;A je izabran iz grupe koju čine fenil, piridil, pirazolil, indolil, tienil, benzotienil, indazolil, benzizoksazolil, benzofuranil, benzotriazolil, furanil, benzotiazolil, tiazolil, svaki izborno supstituisan sa jednom ili dve grupe nezavisno izabrane iz grupe koju čine OH, C1-6 alkil, C3-6 cikloalkil, ili halogen;Q je izabran iz grupe koju čine fenil, piridil, tiazolil, tiofenil, pirimidil, svaki izborno supstituisan sa jednom ili dve grupe nezavisno izabrane iz grupe koju čini C1-6 alkil, halogen ili CF3;gdeX= CH, N, NO;R1 je izabran iz grupe koju čine vodonik, C1-C3 alkil, C3-C6 cikloalkil, C4-C5 alkilcikloalkil, gde C1-3 alkil je izborno supstituisan sa 1 do 3 supstituenta nezavisno izabrana od halogena, hidroksi ili C1-6 alkoksi;R2 i R3 su nezavisno izabrani iz grupe koju čini vodonik, C1-C3 alkil, C1-C3 haloalkil, C1-C3 alkoksi, C1-C3 haloalkoksi i halogen.
2. Jedinjenje prema patentnom zahtevu 1 gde R je izabran iz grupe koju čini COOR6, CONR7R8, tetrazolil ili H, sa R6, R7 i R8 nezavisno izabran iz grupe koju čini H i C1-6 alkil; A je izabran iz grupe koju čini fenil, piridil, indolil, tienil, benzotienil, indazolil, benzizoksazolil, benzofuranil, benzotriazolil, furanil, benzotiazolil, tiazolil, svaki izborno supstituisan sa jednom ili dve grupe nezavisno izabran iz grupe koju čini OH, C1-6 alkil i C3-6 cikloalkil; Q je izabrani iz grupe koju čini fenil, piridil, tiazolil, tiofenil, pirimidil, svaki izborno supstituisan sa jednom ili dve grupe nezavisno izabran iz grupe koju čini C1-6 alkil, halogen i CF3; gde X= CH, N, NO; R1 je izabran iz grupe koju čini vodonik, C1-C3 alkil, C1-C3 haloalkil, C3-C6 cikloalkil i C4-C5 alkilcikloalkil; R2 i R3 su nezavisno izabrani iz grupe koju čini vodonik, C1-C3 alkil, C1-C3 haloalkil, C1-C3 alkoksi, C1-C3 haloalkoksi i halogen.
3. Jedinjenje prema patentnom zahtevu 1 ili 2, sa sledećom strukturom gde X1 je CH ili N; R4 i R5 su nezavisno izabrani iz grupe koju čini H, C1-6 alkil, halogen i CF3; R-A je izabran od ili R1 je izabran iz grupe koju čini izopropil, t-butil i ciklopropil; R2 i R3 su nezavisno izabrani iz grupe koju čini halogen, C1-C3 alkil, metoksi i trifluorometoksi.
4. Jedinjenje prema bilo kom od patentnih zahteva 1 do 3, gde A je fenil; Q je izborno supstituisani fenil, poželjno supstituisan sa jednim supstituentom, poželjno halogenom; X je CH; R1 je cikloalkil; i R2 i R3 svaki su halogen.
5. Jedinjenje prema bilo kom od patentnih zahteva 1 do 4 izabrano od: 3-((2-(2-hloro-4-((5-ciklopropil-3-(2,6-dihlorofenil)izoksazol-4-il)metoksi)fenil)ciklopropil)benzojeve kiseline (-)-3-((2-(2-hloro-4-((5-ciklopropil-3-(2,6-dihlorofenil)izoksazol-4-il)metoksi)fenil)ciklopropil)benzojeve kiseline (+)-3-(2-(2-hloro-4-((5-ciklopropil-3-(2,6-dihlorofenil)izoksazol-4-il)metoksi)fenil)ciklopropil)benzojeve kiseline 3-((2-(2-hloro-4-((3-(2,6-dihlorofenil)-5-izopropilizoksazol-4-il)metoksi)fenil)ciklopropil)benzojeve kiseline 3-((2-(2-hloro-4-((5-ciklopropil-3-(3,5-dihloropiridin-4-il)izoksazol-4-il)metoksi)fenil)ciklopropil)benzojeve kiseline 4-((4-((4-(2-(3-carboksifenil)ciklopropil)-3-hlorophenoksi)metil)-5-ciklopropilizoksazol-3-il)-3,5-dihloropiridin 1-oksida 3-((2-(2-hloro-4-((1-(2,6-dihlorofenil)-4-izopropil-1H-1,2,3-triazol-5-il)metoksi)fenil)ciklopropil)benzojeve kiseline 4-(((4-(2-(6-(1H-tetrazol-5-il)piridin-3-il)ciklopropil)-3-hlorophenoksi)metil)-5-ciklopropil-3-(2,6-dihlorofenil)izoksazola 5-((2-(2-hloro-4-((5-ciklopropil-3-(2,6-dihlorofenil)izoksazol-4-il)metoksi)fenil)ciklopropil)pikolinske kiseline.
6. Jedinjenje prema bilo kom od patentnih zahteva 1 do 4 izabrano od 3-((2-(6-((5-ciklopropil-3-(2,6-dihlorofenil)izoksazol-4-il)metoksi)-2-(trifluorometil)piridin-3-il)ciklopropil)benzojeve kiseline 4-((2-(2-hloro-4-((5-ciklopropil-3-(2,6-dihlorofenil)izoksazol-4-il)metoksi)fenil)ciklopropil)benzojeve kiseline 1,3-dihidroksi-2-(hidroksimetil)propan-2-aminijum 4-(2-(2-hloro-4-((5-ciklopropil-3-(2,6-dihlorofenil)izoksazol-4-il)metoksi)fenil)ciklopropil)benzoata (+)-4-(2-(2-hloro-4-((5-ciklopropil-3-(2,6-dihlorofenil)izoksazol-4-il)metoksi)fenil)ciklopropil)benzojeve kiseline (-)-4-((2-(2-hloro-4-((5-ciklopropil-3-(2,6-dihlorofenil)izoksazol-4-il)metoksi)fenil)ciklopropil)benzojeve kiseline 6-((2-(2-hloro-4-((5-ciklopropil-3-(2,6-dihlorofenil)izoksazol-4-il)metoksi)fenil)ciklopropil)-1-metil-1H-indazol-3-karboksilne kiseline (+)-6-(2-(2-hloro-4-((5-ciklopropil-3-(2,6-dihlorofenil)izoksazol-4-il)metoksi)fenil)ciklopropil)-1-metil-1H-indazol-3-karboksilne kiseline (-)-6-((2-(2-hloro-4-((5-ciklopropil-3-(2,6-dihlorofenil)izoksazol-4-il)metoksi)fenil)ciklopropil)-1-metil-1H-indazol-3-karboksilne kiseline 4-((2-(2-hloro-4-((5-ciklopropil-3-(2,6-dihlorofenil)izoksazol-4-il)metoksi)fenil)ciklopropil)-N-(metilsulfonil)benzamida 2-((4-(2-(2-hloro-4-((5-ciklopropil-3-(2,6-dihlorofenil)izoksazol-4-il)metoksi)fenil)ciklopropil)benzamido)etansulfo kiseline 4-(((4-(2-(4-(1H-tetrazol-5-il)fenil)ciklopropil)-3-hloropenoksi)metil)-5-ciklopropil-3-(2,6-dihlorofenil)izoksazola 4-((2-(2-hloro-4-((3-(2,6-dihlorofenil)-5-(2-hidroksipropan-2-il)izoksazol-4-il)metoksi)fenil)ciklopropil)benzojeve kiseline 5-((2-(2-hloro-4-((5-ciklopropil-3-(2,6-dihlorofenil)izoksazol-4-il)metoksi)fenil)ciklopropil)-1-izopropil-1H-pirazol-3-karboksilne kiseline 6-((2-(2-hloro-4-((5-ciklopropil-3-(2,6-dihlorofenil)izoksazol-4-il)metoksi)fenil)ciklopropil)-1-izopropil-1H-indazol-3-karboksilne kiseline 4-((2-(2-hloro-4-((5-ciklopropil-3-(2,6-dihlorofenil)izoksazol-4-il)metoksi)fenil)ciklopropil)-2,6-dimetilbenzojeve kiseline 4-((2-(2-hloro-4-((5-ciklopropil-3-(2-(trifluorometoksi)fenil)izoksazol-4-il)metoksi)fenil)ciklopropil)benzojeve kiseline (+)-2-(4-(2-(2-hloro-4-((5-ciklopropil-3-(2,6-dihlorofenil)izoksazol-4-il)metoksi)fenil)ciklopropil)benzamido)etansulfokiseline (-)-2-((4-(2-(2-hloro-4-((5-ciklopropil-3-(2,6-dihlorofenil)izoksazol-4-il)metoksi)fenil)ciklopropil)benzamido)etansulfokiseline 2-((4-(2-(2-hloro-4-((5-ciklopropil-3-(2,6-dihlorofenil)izoksazol-4-il)metoksi)fenil)ciklopropil)benzamido)sirćetne kiseline 4-((2-(2-hloro-4-((4-(2,6-dihlorofenil)-1-izopropil-1H-1,2,3-triazol-5-il)metoksi)fenil)ciklopropil)benzojeve kiseline.
7. Jedinjenje prema bilo kom od patentnih zahteva 1 do 6 za korišćenje u profilaksi i/ili tretmanu bolesti posredovanih sa FXR.
8. Jedinjenje prema patentnom zahtevu 7 za upotrebu u profilaksi i/ili tretmanu intrahepatičkog ili nekih drugih oblika ekstrahepatičkih holestatičnih stanja, ili fibroze jetre koja je rezultat hroničnih holestatičnih stanja ili akutnih intrahepatičkih holestatičnih stanja; i/ili za upotrebu u profilaksi i/ili tretmanu opstruktivnih ili hroničnih inflamatornih bolesti jetre; i/ili za upotrebu u profilaksi i/ili tretmanu ciroze jetre; i/ili za upotrebu u profilaksi i/ili tretmanu steatoze jetre i povezanih sindroma, holestatičnih ili fibrotičkih efekata koji su povezani sa cirozom jetre izazvane alkoholom ili sa virusnim oblikom hepatitisa; i/ili za upotrebu u profilaksi i/ili lečenju otkazivanja jetre ili ishemije jetre nakon velike hirurške intervencije na jetre; i/ili za upotrebu u profilaksi i/ili tretmanu steatohepatitisa povezanog sa hemoterapijom (CASH); i/ili za upotrebu u profilaksi i/ili tretmanu akutnog otkazivanja jetre; i/ili za upotrebu u profilaksi i/ili tretmanu inflamatorne bolesti creva.
9. Jedinjenje prema patentnom zahtevu 7 za upotrebu u profilaksi i/ili tretmanu poremećaja lipida i lipoproteina; i/ili za upotrebu u profilaksi i/ili tretmanu dijabetesa tipa II i kliničkih komplikacija tipa I i tipa II dijabetesa, uključujući dijabetičku nefropatiju, dijabetičku neuropatiju, dijabetičku retinopatiju i druge uočene efekte klinički manifestovane kod dugotrajnog dijabetesa; i/ili za upotrebu u profilaksi i/ili tretmanu stanja i bolesti koji rezultuju iz hronične masne i fibrotičke degeneracije organa usled akumulacije lipida i specifično triglicerida i naknadne aktivacije profibrotičkih puteva, kao što je bolest ne-alkoholna masna jetra (NAFLD), ili ne-alkoholni steatohepatitis (NASH); i/ili za upotrebu u profilaksi i/ili tretmanu gojaznosti ili metaboličkog sindroma (kombinovana stanja dislipidemije, dijabetesa ili abnormalno visokog indeksa telesne mase); i/ili za upotrebu u profilaksi i/ili tretmanu akutnog infarkta miokarda, akutnog šloga, ili tromboze koja se dešava kao krajnji ishod hronične opstruktivne ateroskleroze.
10. Jedinjenje prema patentnom zahtevu 7 za upotrebu u profilaksi i/ili tretmanu ne-malignih hiperproliferativnih poremećaja i malignih hiperproliferativnih poremećaja, specifično hepatocelularnog karcinoma, adenoma debelog creva i polipoze, adenokarcinoma debelog creva, raka dojke, adenokarcinoma pankreasa, Barrett-ovog ezofagusa i drugih oblika neoplastičnih bolesti gastrointestinalnog trakta i jetre.
11. Upotreba jedinjenja prema bilo kom od patentnih zahteva 1 do 6 za pripremu medikamenta za profilaksu i/ili tretman bolesti posredovanih sa FXR.
12. Upotreba prema patentnom zahtevu 11 za profilaksu i/ili tretman hroničnih intrahepatičkih ili nekih drugih ekstrahepatičkih holestatičnih stanja, ili fibroze jetre koja je rezultat hroničnih holestatičnih stanja ili akutnih holestatičnih stanja; i/ili za upotrebu u profilaksi i/ili tretmanu opstruktivnih ili hroničnih inflamatornih bolesti jetre; i/ili za upotrebu u profilaksi i/ili tretmanu ciroze jetre; i/ili za upotrebu u profilaksi i/ili tretmanu steatoze jetre i povezanih sindroma, holestatičnih ili fibrotičkih efekata koji su povezani sa cirozom jetre izazvane alkoholom ili sa virusnim oblikom hepatitisa; i/ili za upotrebu u profilaksi i/ili lečenju otkazivanja jetre ili ishemije jetre nakon velike hirurške intervencije na jetre; i/ili za upotrebu u profilaksi i/ili tretmanu steatohepatitisa povezanog sa hemoterapijom (CASH); i/ili za upotrebu u profilaksi i/ili tretmanu akutnog otkazivanja jetre; i/ili za upotrebu u profilaksi i/ili tretmanu inflamatorne bolesti creva.
13. Upotreba prema patentnom zahtevu 11 za profilaksu i/ili tretman poremećaja lipida ili lipoproteina; i/ili za upotrebu u profilaksi i/ili tretmanu dijabetesa tipa II i kliničkih komplikacija tipa I i tipa II dijabetesa, uključujući dijabetičku nefropatiju, dijabetičku neuropatiju, dijabetičku retinopatiju i druge uočene efekte klinički manifestovane kod dugotrajnog dijabetesa; i/ili za upotrebu u profilaksi i/ili tretmanu stanja i bolesti koji rezultuju iz hronične masne i fibrotičke degeneracije organa usled akumulacije lipida i specifično triglicerida i naknadne aktivacije profibrotičkih puteva, kao što je bolest ne-alkoholna masna jetra (NAFLD), ili ne-alkoholni steatohepatitis (NASH); i/ili za upotrebu u profilaksi i/ili tretmanu gojaznosti ili metaboličkog sindroma (kombinovana stanja dislipidemije, dijabetesa ili abnormalno visokog indeksa telesne mase); i/ili za upotrebu u profilaksi i/ili tretmanu akutnog infarkta miokarda, akutnog šloga, ili tromboze koja se dešava kao krajnji ishod hronične opstruktivne ateroskleroze.
14. Upotreba prema patentnom zahtevu 11 za profilaksu i/ili tretman ne-malignih hiperproliferativnih poremećaja i malignih hiperproliferativnih poremećaja, specifično hepatocelularnog karcinoma, adenoma debelog creva i polipoze, adenokarcinoma debelog creva, raka dojke, adenokarcinoma pankreasa, Barrett-ovog ezofagusa i drugih oblika neoplastičnih bolesti gastrointestinalnog trakta i jetre.
15. Jedinjenje prema bilo kom od patentnih zahteva 1 do 6 za upotrebu kao medikamenta.
MEP-2015-18A 2009-08-19 2010-08-19 Nova jedinjenja koja se vezuju za fxr (nr1 h4) i moduliraju njegovu aktivnost ME02047B (me)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23511709P 2009-08-19 2009-08-19
EP09010676A EP2289883A1 (en) 2009-08-19 2009-08-19 Novel FXR (NR1H4) binding and activity modulating compounds
EP10747171.6A EP2467366B1 (en) 2009-08-19 2010-08-19 Novel fxr (nr1h4) binding and activity modulating compounds
PCT/EP2010/005093 WO2011020615A1 (en) 2009-08-19 2010-08-19 Novel fxr (nr1h4 ) binding and activity modulating compounds

Publications (1)

Publication Number Publication Date
ME02047B true ME02047B (me) 2015-05-20

Family

ID=41137753

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2015-18A ME02047B (me) 2009-08-19 2010-08-19 Nova jedinjenja koja se vezuju za fxr (nr1 h4) i moduliraju njegovu aktivnost

Country Status (30)

Country Link
US (1) US8952042B2 (me)
EP (2) EP2289883A1 (me)
JP (1) JP5692934B2 (me)
KR (1) KR101712466B1 (me)
CN (1) CN102548974B (me)
AU (1) AU2010285175B2 (me)
BR (1) BR112012003554A2 (me)
CA (1) CA2771445C (me)
CL (1) CL2012000369A1 (me)
DK (1) DK2467366T3 (me)
EA (1) EA024083B1 (me)
ES (1) ES2529226T3 (me)
GE (1) GEP20146109B (me)
HR (1) HRP20150159T1 (me)
IL (1) IL217676A (me)
IN (1) IN2012DN00790A (me)
MA (1) MA33575B1 (me)
ME (1) ME02047B (me)
MX (1) MX2012002119A (me)
MY (1) MY163109A (me)
NZ (1) NZ598328A (me)
PL (1) PL2467366T3 (me)
PT (1) PT2467366E (me)
RS (1) RS53812B1 (me)
SG (1) SG178336A1 (me)
SI (1) SI2467366T1 (me)
SM (1) SMT201500029B (me)
UA (1) UA108209C2 (me)
WO (1) WO2011020615A1 (me)
ZA (1) ZA201200730B (me)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24152B1 (es) * 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
EP2545964A1 (en) * 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
IL253437A0 (en) * 2011-07-13 2017-09-28 Gilead Sciences Inc New compounds modulate fxr (nr1h4) activity and bind
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
WO2014001278A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014001280A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014001279A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
BR112014032501A2 (pt) 2012-06-26 2017-06-27 Saniona Aps composto, e, composição farmacêutica.
AU2013283487C1 (en) 2012-06-26 2018-01-18 Saniona Aps A phenyl triazole derivative and its use for modulating the GABAA receptor complex
JO3215B1 (ar) 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
CN102976946A (zh) * 2012-12-13 2013-03-20 烟台泰和新材料股份有限公司 合成间苯二甲酸二甲酯的方法
CN103232378B (zh) * 2013-04-27 2015-11-18 国家海洋局第三海洋研究所 一种含6-溴吲哚满二酮的荔枝螺提取物及制备方法与其抗癌应用
DK3043865T3 (da) 2013-09-11 2021-02-01 Univ Claude Bernard Lyon Fremgangsmåder og farmaceutiske sammensætningr til behandlingen af hepatitis b-virusinfektion
NZ729678A (en) 2014-09-24 2018-07-27 Gilead Sciences Inc Methods of treating non-alcoholic steatohepatitis using ask1 inhibitor in combination with a fxr agonist
EP3006939A1 (en) 2014-10-06 2016-04-13 Gilead Sciences, Inc. Histidine-rich Glycoprotein as a marker for hepatic Farnesoid X receptor activation
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
EP3034499A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Novel FXR (NR1H4) modulating compounds
EP3034501A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy containing FXR (NR1H4) modulating compounds
CN107405325B (zh) 2015-02-06 2021-11-12 英特塞普特医药品公司 用于组合疗法的药物组合物
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
MX379579B (es) 2015-03-31 2025-03-11 Enanta Pharm Inc Derivados de ácido biliar como agonistas de fxr/tgr5 y métodos para su uso.
AU2016246524B2 (en) 2015-04-07 2021-04-01 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions for combination therapy
WO2017128896A1 (zh) * 2016-01-26 2017-08-03 江苏豪森药业集团有限公司 Fxr激动剂及其制备方法和应用
CN106995416A (zh) * 2016-01-26 2017-08-01 上海翰森生物医药科技有限公司 Fxr激动剂及其制备方法和应用
CN107021957A (zh) * 2016-02-01 2017-08-08 山东轩竹医药科技有限公司 Fxr受体激动剂
KR20180124123A (ko) 2016-03-28 2018-11-20 인터셉트 파마슈티컬즈, 인크. Fxr 효능제 및 arb의 조합에 의해 얻어지는 의약
WO2017189652A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US10080742B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US10080743B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US10144729B2 (en) 2016-05-18 2018-12-04 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
WO2017201152A1 (en) * 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US10149835B2 (en) 2016-05-18 2018-12-11 Elmore Patent Law Group, P.C. Isoxazole derivatives as FXR agonists and methods of use thereof
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
EP3468962A1 (en) * 2016-06-13 2019-04-17 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
AR108711A1 (es) * 2016-06-13 2018-09-19 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4)
TW201808283A (zh) 2016-08-05 2018-03-16 廣東東陽光藥業有限公司 含氮三環化合物及其在藥物中的應用
CN106237332A (zh) * 2016-08-11 2016-12-21 河南大学 核受体fxr在肝癌干细胞靶向治疗中的应用
EP3954684A1 (en) 2016-08-23 2022-02-16 Ardelyx, Inc. Process for the preparation of hormone receptor modulators for treating metabolic conditions and disorders
US11091482B2 (en) 2016-08-23 2021-08-17 Ardelyx, Inc. Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators
CN109689050A (zh) * 2016-09-14 2019-04-26 诺华股份有限公司 Fxr激动剂的新方案
KR20180036522A (ko) * 2016-09-30 2018-04-09 (주)나노믹스 스틸벤 유도체 및 그 제조 방법
US10450306B2 (en) 2016-10-04 2019-10-22 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
CN107973790A (zh) * 2016-10-22 2018-05-01 合帕吉恩治疗公司 杂环fxr调节剂
US10597391B2 (en) 2016-10-26 2020-03-24 Enanta Pharmaceuticals, Inc. Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof
CN106588804B (zh) * 2016-12-09 2018-11-09 都创(上海)医药科技有限公司 一种作为类法尼醇x受体(fxr)的化合物的制备方法
CN109071468B (zh) * 2017-01-20 2022-09-02 四川科伦博泰生物医药股份有限公司 一种杂环化合物及其制备方法和用途
JP7618384B2 (ja) 2017-02-21 2025-01-21 ジェンフィ Ｐｐａｒアゴニストとｆｘｒアゴニストとの組合せ
EP4424364A3 (en) 2017-03-28 2024-11-27 Gilead Sciences, Inc. Methods of treating liver disease
US20210085662A1 (en) 2017-03-30 2021-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses
MX388300B (es) 2017-04-07 2025-03-19 Enanta Pharm Inc Proceso para la preparación de derivados de ácidos biliares de sulfonil carbamato
PT3612520T (pt) * 2017-04-12 2022-01-06 Il Dong Pharma Derivados de isoxazol como agonistas de recetores nucleares e utilizações dos mesmos
WO2018190643A1 (en) * 2017-04-12 2018-10-18 Il Dong Pharmaceutical Co., Ltd. An isoxazole derivatives as nuclear receptor agonists and used thereof
CN110662743B (zh) 2017-05-26 2022-09-30 石药集团中奇制药技术（石家庄）有限公司 作为fxr受体激动剂的内酰胺类化合物
JP6997870B2 (ja) 2017-07-06 2022-02-10 シュアンチュー バイオファーマシューティカル カンパニー，リミティド Ｆｘｒ受容体刺激薬
MA50242A (fr) * 2017-09-14 2020-07-22 Ardelyx Inc Modulateurs du récepteur hormonal pour le traitement d'états et de troubles métaboliques mutagènes et fibrotiques
ES2944657T3 (es) 2017-11-01 2023-06-23 Bristol Myers Squibb Co Compuestos de alqueno como moduladores del receptor farnesoide X
WO2019089665A1 (en) 2017-11-01 2019-05-09 Bristol-Myers Squibb Company Alkene spirocyclic compounds as farnesoid x receptor modulators
CN111278817B (zh) 2017-11-01 2023-05-16 百时美施贵宝公司 作为法尼醇x受体调节剂的多环化合物
WO2019118571A1 (en) 2017-12-12 2019-06-20 Enanta Pharmaceuticals, Inc. Isoxazole analogs as fxr agonists and methods of use thereof
CN110128432B (zh) 2018-02-02 2021-03-02 广东东阳光药业有限公司 含氮三环化合物及其在药物中的应用
US10829486B2 (en) 2018-02-14 2020-11-10 Enanta Pharmacueticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
EP3787669A4 (en) * 2018-04-30 2022-03-30 The Trustees of Indiana University Compounds for modulating ddah and adma levels, as well as methods of using thereof to treat disease
BR102019014802A2 (pt) 2018-07-20 2020-02-04 Boehringer Ingelheim Int difluorometil-fenil triazóis
CN112638473B (zh) 2018-08-08 2022-06-07 因奥必治疗有限公司 用于调节类法尼醇x受体的化合物以及制备和使用所述化合物的方法
AU2020209564B2 (en) 2019-01-15 2022-12-01 Gilead Sciences, Inc. FXR (NR1H4) modulating compounds
CN112955448B (zh) 2019-01-31 2023-02-03 中国医药研究开发中心有限公司 芳环或芳杂环类化合物及其制备方法和医药用途
CN118388474A (zh) 2019-02-19 2024-07-26 吉利德科学公司 Fxr激动剂的固体形式
WO2020231917A1 (en) 2019-05-13 2020-11-19 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
CA3142358A1 (en) 2019-05-30 2020-12-03 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease
KR20220035365A (ko) 2019-07-18 2022-03-22 엔요 파마 인터페론의 부작용을 감소시키는 방법
CN114945361A (zh) 2020-01-15 2022-08-26 法国国家卫生及研究医学协会 Fxr激动剂在治疗丁型肝炎病毒感染中的用途
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
CN113754541B (zh) * 2020-06-02 2025-01-03 深圳湾实验室 靶向eb病毒核抗原蛋白的小分子抑制剂、制备方法及其应用
CN114656460B (zh) 2020-12-22 2025-01-10 江苏天士力帝益药业有限公司 一种新型吡嗪结构fxr激动剂、制备方法及应用
AU2022209084A1 (en) 2021-01-14 2023-08-10 Centre Leon Bérard Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection
WO2022229302A1 (en) 2021-04-28 2022-11-03 Enyo Pharma Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment
WO2023090858A1 (ko) * 2021-11-17 2023-05-25 일동제약(주) 아이속사졸 유도체의 제조 방법 및 그의 중간체
WO2023090859A1 (ko) * 2021-11-17 2023-05-25 일동제약(주) 아이속사졸 유도체의 제조 방법 및 그의 신규한 중간체
KR102740618B1 (ko) * 2021-11-17 2024-12-10 유노비아 주식회사 아이속사졸 유도체의 제조 방법 및 그의 중간체
WO2024005586A1 (ko) * 2022-06-30 2024-01-04 일동제약(주) 아이속사졸 유도체 또는 이의 염의 신규한 결정형

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2326850T3 (es) 1998-12-23 2009-10-20 Glaxo Group Limited Ensayos para ligandos de receptores nucleares.
EP1285914B1 (en) 2001-08-13 2007-12-19 PheneX Pharmaceuticals AG Nr1h4 nuclear receptor binding compounds
WO2003080803A2 (en) 2002-03-21 2003-10-02 Smithkline Beecham Corporation Methods of using farnesoid x receptor (fxr) agonists
US7319109B2 (en) 2002-11-22 2008-01-15 Smith Kline Beecham Corporation Farnesoid X receptor agonists
WO2004087076A2 (en) 2003-03-31 2004-10-14 The Rockefeller University Methods for inhibiting adipogenesis and for treating type 2 diabetes
ATE526318T1 (de) 2005-12-19 2011-10-15 Glaxosmithkline Llc Farnesoid-x-rezeptor-agonisten
CN101374834B (zh) 2006-02-03 2011-12-14 伊莱利利公司 用于调节fxr的化合物和方法
DK2029547T3 (da) 2006-05-24 2010-07-26 Lilly Co Eli FXR-agonister
EP2029558B1 (en) 2006-05-24 2010-03-10 Eli Lilly And Company Compounds and methods for modulating fxr
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
CL2007003035A1 (es) 2006-10-24 2008-05-16 Smithkline Beechman Corp Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
CN101977505A (zh) 2007-06-13 2011-02-16 葛兰素史密丝克莱恩有限责任公司 类法尼醇x受体激动剂
KR20100044810A (ko) 2007-07-02 2010-04-30 글락소스미스클라인 엘엘씨 파네소이드 ｘ 수용체 효능제
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR

Also Published As

Publication number Publication date
EP2289883A1 (en) 2011-03-02
SG178336A1 (en) 2012-03-29
JP2013502389A (ja) 2013-01-24
US8952042B2 (en) 2015-02-10
US20120232116A1 (en) 2012-09-13
CA2771445C (en) 2017-09-12
IN2012DN00790A (me) 2015-06-26
HK1172325A1 (en) 2013-04-19
CA2771445A1 (en) 2011-02-24
GEP20146109B (en) 2014-06-10
MX2012002119A (es) 2012-08-23
SI2467366T1 (sl) 2015-03-31
IL217676A (en) 2015-11-30
KR20120080574A (ko) 2012-07-17
EP2467366A1 (en) 2012-06-27
EA024083B1 (ru) 2016-08-31
BR112012003554A2 (pt) 2020-01-28
EA201290047A1 (ru) 2013-09-30
PL2467366T3 (pl) 2015-04-30
NZ598328A (en) 2013-04-26
UA108209C2 (uk) 2015-04-10
ES2529226T3 (es) 2015-02-18
PT2467366E (pt) 2015-02-06
JP5692934B2 (ja) 2015-04-01
MY163109A (en) 2017-08-15
CN102548974A (zh) 2012-07-04
WO2011020615A1 (en) 2011-02-24
AU2010285175A1 (en) 2012-02-23
MA33575B1 (fr) 2012-09-01
HRP20150159T1 (hr) 2015-05-22
KR101712466B1 (ko) 2017-04-06
CL2012000369A1 (es) 2012-07-13
EP2467366B1 (en) 2014-11-12
RS53812B1 (sr) 2015-06-30
ZA201200730B (en) 2012-09-26
CN102548974B (zh) 2015-11-25
AU2010285175B2 (en) 2014-11-27
DK2467366T3 (en) 2015-02-16
SMT201500029B (it) 2015-03-05

Similar Documents

Publication Publication Date Title
ME02047B (me) Nova jedinjenja koja se vezuju za fxr (nr1 h4) i moduliraju njegovu aktivnost
ME02434B (me) Nova jedinjenja koja moduliraju fxr (nr1h4)
JP2014520823A5 (me)
HRP20191561T1 (hr) Spojevi za modulaciju fxr (nr1h4)
JP6935064B2 (ja) Ｇｐｒ１２０アゴニストとしてのビアリール誘導体
IL274816B2 (en) Sulfone pyridine alkyl amide-substituted heteroaryl compounds
US8008292B2 (en) Condensed benzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity
JP2010513397A5 (me)
JP5040656B2 (ja) トリアリールカルボン酸誘導体
JP2006518763A5 (me)
JP2011502982A5 (me)
JP5667297B2 (ja) ヘテロアリールメチルアミド
EP2375904B1 (en) Biaryl carboxamides
CN114728168A (zh) 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途
JP2009519965A5 (me)
EA033642B1 (ru) Соединения, модулирующие fxr (nr1h4)
JP2010515691A5 (me)
JP2019531274A5 (me)
JP2012504141A5 (me)
CN111032647B (zh) 溶血磷脂酸受体1(lpar1)抑制剂化合物
CA2651378A1 (en) Fxr agonists
JP2021512114A5 (me)
HRP20180546T1 (hr) Supstituirani benzilindazoli za uporabu kao inhibitori bub1 kinaze za liječenje hiperproliferativnih bolesti
RU2013142011A (ru) З-аминопиридины в качестве агонистов gpbar1
JP2017514856A5 (me)